US Pharma MarketingBioMarin does another small deal to get early-stage bone disease asset
A week after ending development of a rare disease drug from a $270 million acquisition, BioMarin is back at the dealmaking table for a very similar number. The California biopharma
A week after ending development of a rare disease drug from a $270 million acquisition, BioMarin is back at the dealmaking table for a very similar number.
The California biopharma
Source: Endpoints News